Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jules Lavalaye

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
The Prostate|May 5, 2024
The additional value of <sup>68</sup>Ga-PSMA PET/CT SUVmax in predicting ISUP GG ≥ 2 and ISUP GG ≥ 3 prostate cancer in biopsyJoris G Heetman, Leonor J Paulino Pereira, Johannes C Kelder, et al.
Annals of Surgical Oncology|February 5, 2026
ASO Visual Abstract: The Clinical Impact of the Surgical Removal of the Internal Mammary Chain Sentinel Node in Breast Cancer Patients: Do We Need to De-Escalate Our Former Strategy? Reevaluating the Role of Internal Mammary Sentinel Node Removal in Breast Cancer SurgeryEmilie M A L C Fentener van Vlissingen, Emily L Postma, Astrid N Scholten, et al.
Annals of Surgical Oncology|January 4, 2026
The Clinical Impact of the Surgical Removal of the Internal Mammary Chain Sentinel Node in Breast Cancer Patients: Do We Need to De-Escalate our Former Strategy?Emilie M A L C Fentener van Vlissingen, Emily L Postma, Astrid N Scholten, et al.
The Journal of Urology|December 4, 2019
Reply by AuthorsLudwike W M van Kalmthout, Harm H E van Melick, Jules Lavalaye, et al.
The Journal of Urology|September 6, 2019
Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate CancerLudwike W M van Kalmthout, Harm H E van Melick, Jules Lavalaye, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 12, 2019
Healthy Tissue Uptake of <sup>68</sup>Ga-Prostate-Specific Membrane Antigen, <sup>18</sup>F-DCFPyL, <sup>18</sup>F-Fluoromethylcholine, and <sup>18</sup>F-DihydrotestosteroneBernard H E Jansen, Gem M Kramer, Matthijs C F Cysouw, et al.
Scientific Reports|April 11, 2025
The Conundrum of Treating de novo metastatic Hormone-Sensitive Prostate CancerTessa van Elst, Niven Mehra, Sjaak Bloem, et al.
Critical Care (London, England)|April 10, 2026
Determinants of diagnostic yield and scan quality of [<sup>18</sup>F]FDG PET/CT in critically ill patients suspected of infection or inflammation of unknown originJelle L G Haitsma Mulier, Bram van Leer, Joanne J Beijer-Verduin, et al.
Clinical Genitourinary Cancer|December 1, 2021
Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the NetherlandsMalou C P Kuppen, Hans M Westgeest, Alfons J M van den Eertwegh, et al.
Future Oncology (London, England)|May 30, 2020
Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancerMalou Cp Kuppen, Hans M Westgeest, Maarten J van der Doelen, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
The Prostate|May 5, 2024
The additional value of <sup>68</sup>Ga-PSMA PET/CT SUVmax in predicting ISUP GG ≥ 2 and ISUP GG ≥ 3 prostate cancer in biopsyJoris G Heetman, Leonor J Paulino Pereira, Johannes C Kelder, et al.
Annals of Surgical Oncology|February 5, 2026
ASO Visual Abstract: The Clinical Impact of the Surgical Removal of the Internal Mammary Chain Sentinel Node in Breast Cancer Patients: Do We Need to De-Escalate Our Former Strategy? Reevaluating the Role of Internal Mammary Sentinel Node Removal in Breast Cancer SurgeryEmilie M A L C Fentener van Vlissingen, Emily L Postma, Astrid N Scholten, et al.
Annals of Surgical Oncology|January 4, 2026
The Clinical Impact of the Surgical Removal of the Internal Mammary Chain Sentinel Node in Breast Cancer Patients: Do We Need to De-Escalate our Former Strategy?Emilie M A L C Fentener van Vlissingen, Emily L Postma, Astrid N Scholten, et al.
The Journal of Urology|December 4, 2019
Reply by AuthorsLudwike W M van Kalmthout, Harm H E van Melick, Jules Lavalaye, et al.
The Journal of Urology|September 6, 2019
Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate CancerLudwike W M van Kalmthout, Harm H E van Melick, Jules Lavalaye, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 12, 2019
Healthy Tissue Uptake of <sup>68</sup>Ga-Prostate-Specific Membrane Antigen, <sup>18</sup>F-DCFPyL, <sup>18</sup>F-Fluoromethylcholine, and <sup>18</sup>F-DihydrotestosteroneBernard H E Jansen, Gem M Kramer, Matthijs C F Cysouw, et al.
Scientific Reports|April 11, 2025
The Conundrum of Treating de novo metastatic Hormone-Sensitive Prostate CancerTessa van Elst, Niven Mehra, Sjaak Bloem, et al.
Critical Care (London, England)|April 10, 2026
Determinants of diagnostic yield and scan quality of [<sup>18</sup>F]FDG PET/CT in critically ill patients suspected of infection or inflammation of unknown originJelle L G Haitsma Mulier, Bram van Leer, Joanne J Beijer-Verduin, et al.
Clinical Genitourinary Cancer|December 1, 2021
Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the NetherlandsMalou C P Kuppen, Hans M Westgeest, Alfons J M van den Eertwegh, et al.
Future Oncology (London, England)|May 30, 2020
Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancerMalou Cp Kuppen, Hans M Westgeest, Maarten J van der Doelen, et al.
Pageof 4